Pharmacological inhibition of AT1 receptor function by an ACE inhibitor, an AT1 receptor antagonist, or an ARNI (angiotensin receptor blocker and neprilysin inhibitor) is the mainstay of recommended prognosis-improving therapies of heart failure [4]. The gene discussed is MME; the disease is heart failure.